402MO Final results of the CARACAS study: Randomized phase II trial of avelumab alone or with cetuximab for unresectable, locally advanced or metastatic squamous cell anal carcinoma progressed to at least one line of treatment. - Lonardi, S.; Pietrantonio, F.; Prete, A.A.; Messina, M.; Formica, V.; Corsi, D.C.; Cortesi, E.; Frassineti, L.G.; Zampino, M.G.; Ronzoni, M.; Scartozzi, M.; Casagrande, M.; et al. (Annals of Oncology, 2020)